Table 2. Stratification of estimated effect size for sensorimotor function.
| Variable | # Studies | # Comparisons | SMD (95% CI) |
% Weight | I2 | p* | p** |
|---|---|---|---|---|---|---|---|
| Animal model | |||||||
| Species | |||||||
| Rat | 7 | 25 | 0.99 (0.72–1.27) | 44.62 | 94.5% | 0.000 | 0.002 |
| Mouse | 7 | 29 | 3.19 (2.94–3.44) | 55.38 | 93.6% | 0.000 | |
| Strain | |||||||
| Sprague-Dawley | 6 | 16 | 0.57 (0.25–0.89) | 32.70 | 93.4% | 0.000 | 0.000 |
| C57/Bl6 | 8 | 38 | 3.01 (2.78–3.23) | 67.30 | 94.1% | 0.000 | |
| Gender | |||||||
| Male | 3 | 14 | 0.40 (0.05–0.75) | 27.99 | 93.9% | 0.000 | 0.000 |
| Mixed | 3 | 8 | 3.09 (2.60–3.58) | 13.96 | 92.5% | 0.000 | |
| Not reported | 8 | 32 | 2.87 (2.62–3.11) | 58.05 | 94.4% | 0.000 | |
| Age (at HIE) | |||||||
| < 7 days | 1 | 1 | 1.11 (0.20–2.01) | 4.09 | 0.0% | 0.000 | 0.001 |
| 7 days | 3 | 11 | 0.31 (-0.06–0.68) | 24.35 | 94.9% | 0.000 | |
| > 7 days | 10 | 42 | 2.92 (2.70–3.13) | 71.56 | 94.9% | 0.000 | |
| Study Design | |||||||
| HIE model | |||||||
| CAO + hypoxia | 11 | 45 | 2.41 (2.21–2.60) | 87.08 | 95.0% | 0.000 | 0.081 |
| MCAO | 3 | 9 | 0.87 (0.36–1.38) | 12.92 | 92.4% | 0.000 | |
| Anesthetic | |||||||
| Isoflurane | 10 | 42 | 2.92 (2.70–3.13) | 71.56 | 93.9% | 0.000 | 0.000 |
| Halothane | 1 | 2 | 1.03 (-0.05–2.10) | 2.91 | 0.0% | 0.463 | |
| Ether | 2 | 2 | 1.57 (0.73–2.42) | 4.71 | 87.1% | 0.000 | |
| Ketamine | 1 | 8 | 0.83 (-0.32–0.49) | 20.82 | 96.1% | 0.000 | |
| Intervention | |||||||
| Source | |||||||
| Bone marrow | 8 | 34 | 2.39 (2.16–2.62) | 63.77 | 95.1% | 0.000 | 0.420 |
| Umbilical cord | 4 | 6 | 1.55 (0.94–2.16) | 8.96 | 84.8% | 0.000 | |
| Not reported | 2 | 14 | 2.00 (1.65–2.35) | 27.27 | 95.7% | 0.000 | |
| Origin | |||||||
| Allogeneic | 8 | 38 | 2.81 (2.60–3.04) | 67.35 | 94.1% | 0.000 | 0.003 |
| Xenogeneic | 6 | 16 | 0.95 (0.63–1.27) | 32.65 | 94.9% | 0.000 | |
| Dose | |||||||
| ≤250,000 | 5 | 20 | 3.76 (3.41–4.10) | 28.11 | 90.3% | 0.000 | 0.002 |
| >250,000 - ≤500,000 | 4 | 15 | 2.55 (2.23–2.88) | 31.48 | 95.1% | 0.000 | |
| >500,000 - ≤1 million | 4 | 18 | 0.70 (0.41–0.99) | 39.17 | 94.7% | 0.000 | |
| >1 million | 1 | 1 | 5.97 (4.32–7.62) | 1.24 | 0.0% | 0.000 | |
| Delivery | |||||||
| Intracerebral | 5 | 19 | 4.39 (4.01–4.77) | 23.63 | 85.9% | 0.000 | 0.001 |
| Intranasal | 5 | 23 | 2.19 (1.93–2.46) | 47.93 | 95.1% | 0.000 | |
| Intraperitoneal | 1 | 1 | 1.11 (0.20–2.01) | 4.09 | 0.0% | 0.000 | |
| Intracardiac | 1 | 8 | 0.83 (-0.32–0.49) | 20.81 | 96.1% | 0.000 | |
| Subcutaneous | 1 | 2 | 1.03 (-0.05–2.10) | 2.92 | 0.0% | 0.463 | |
| IV | 1 | 1 | 4.67 (2.33–7.01) | 0.62 | 0.0% | 0.000 | |
| Timing | |||||||
| < 72 hrs | 7 | 25 | 1.45 (1.18–1.73) | 44.66 | 94.7% | 0.000 | 0.003 |
| > 72 hrs | 6 | 16 | 2.01 (1.71–2.33) | 35.16 | 95.4% | 0.000 | |
| Multiple doses | 5 | 13 | 4.22 (3.81–4.63) | 20.18 | 88.7% | 0.000 | |
| Expansion media | |||||||
| DMEM | 8 | 34 | 1.93 (1.70–2.16) | 63.51 | 94.9% | 0.000 | 0.400 |
| HPL | 1 | 2 | 5.37 (4.28–6.45) | 2.86 | 0.0% | 0.341 | |
| Commercial | 1 | 1 | 4.67 (2.33–7.01) | 0.61 | 0.0% | 0.000 | |
| Not reported | 4 | 17 | 2.43 (2.11–2.74) | 33.02 | 4.9% | 0.000 |
Note
*p value for subgroup differences.
**p value for heterogeneity between subgroups with meta-regression analysis.